Patients may be registered to calgb 30610 following one cycle of chemotherapy. Three different radiation therapy regimens in treating. Combination chemotherapy in treating patients with stage iii colon cancer the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Multimodality therapy for limitedstagesmallcelllungcancer. Treated with combination chemotherapy calgb lung nct00698815 pemetrexed andor sunitinib as second. Line therapy in treating patients with stage iiib or stage iv non. Impact of induction chemotherapy on estimated risk of. Calgb 30610, phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin or carboplatin and etoposide protocol version date092717 v.
Calgb 30610 phase ill comparison of thoracic radiotherapy regimens with cisplatin and etoposide in limited small cell lung cancer patient eligibility histologically or cytologically documented small cell lung cancer of limited stage see section 4. Burkitt lymphoma part 1 of 3 the selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. This is a randomized phase ii trial for patients with localized, surgically resectable esophageal cancer designed to evaluate the early assessment of response to chemotherapy by metabolic. Calgb 10603ctsu c10603 2 040108 calgb central office 230 west monroe street, suite 2050 chicago, il 606064703 tel. Calgb 30610, a phase iii randomized controlled trial, was designed to compare three accepted regimens including 45 gy in 30 twicedaily fractions over 3 weeks, 70 gy in 35 daily fractions over seven weeks, and 61.
Announcements from nci and the lpos will be posted as they are received. A phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide. Failing to do all of the above will make the patient not eligible for calgb 30610. To download the pdf, click the download link below. A randomized phase ii trial of myeloablative versus nonmyeloablative consolidation chemotherapy for newly diagnosed primary cns bcell lymphoma arm 1 and arm 2 receive the same induction therapy cycles 15. Calgb 30610 rtog 0538 piyunjie lin, md nct 00632853 coordinatorangie patterson a phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin or carboplatin and etoposide hcrn lun17302 pi maitri kalra, md nct 039455 coordinatorangie patterson. Failing to do all of the above will make the patient not eligible for calgb. Calgb 30610 phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide. The pdf file you selected should load here if your web browser has a pdf reader plugin installed for example, a recent version of adobe acrobat reader. Checklist for submission of radiation oncology quality assurance materials.
Calgb 30105 eligibility criteria have been published previously. Is it time to convert the frequency of radiotherapy in. Calgb 30610 phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin or carboplatin and etoposide a151216 adjuvant lung cancer enrichment marker identification and sequencing trial alchemist a081105 randomized double blind placebo controlled study of. Pulmonary toxicity in stage iii nonsmall cell lung cancer patients treated with highdose 74 gy 3dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and. Adjuvant lung schema protocol informationlink to clinicaltrials. Calgb 100104 2 111511 calgb central office 230 west monroe street, suite 2050 chicago, il 606064703 tel. Radiation dose and fractionation for limitedstage smallcell lung. Calgb 80405 pdf asco, itt, kraswt primary os results. Registration to calgb 30610 must take place within 1421 days after the start of the nonprotocol therapy. Rtog 0538calgb 30610 protocol student doctor network. Lsclc treated on the experimental thoracic radiotherapy trt arms of calgb 30610 alliance rtog 0538.
Listing a study does not mean it has been evaluated by the u. Patients may have received one and only one cycle of chemotherapy prior to enrolling on cancer and leukemia group b calgb 30610, which must have included carboplatin or cisplatin and etoposide. We encourage the study authors to analyse quality of life data for patients as well as caregiver burden, and other research groups to conduct a formal economic analysis. Phase iii comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide protocol informationlink to clinicaltrials. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia. Leukemia group b trials calgb 30904 reported that total. Patients must receive the second cycle of therapy following registration, on day 2224, so that the patient adheres to a 3week treatment cycle. Radiation therapy regimens in treating patients with.
Interruptions of oncedaily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer. Combination chemotherapy in treating patients with stage. Prophylactic cranial irradiation overview collaborative group. Ea6141, randomized phase iiiii study of nivolumab plus ipilimumab plus sargramostim. Additional information from nci is available on the ctep coronavirus guidance page. As a service to our customers we are providing this early version of the manuscript. This is a pdf file of an unedited manuscript that has been accepted for publication. A phase ii study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell.
Looks like it has been removed from the rtog website. Management of all in adults national cancer institute. Ea11 a randomized phase iii postoperative trial of platinum based chemotherapy vs. Calgb 30610 rtog 0538 limited small cell 45 gy bid 3 weeks 61. Calgb 30610rtog 0538 started as a 3 arm study designed to discontinue one of 2 ex. Briefly, patients with histologically or cytologically confirmed stage iiiaiiib ajcc 2000 unresectable nsclc, eastern cooperative oncology group ecog performance status ps of 01, and normal organ and marrow function were eligible. Prophylactic cranial irradiation for patients with smallcell lung cancer in complete remission. Interim toxicity analysis for patients with limited. Calgb failed to meet its primary endpoint of os cetuximab is not superior to avastin in 1l kraswt. Interim toxicity analysis for patients with limited stage small cell lung. No prior radiotherapy or chemotherapy except for the chemotherapy described in the bullet above for sclc.
Christakis, for the cancer and leukemia group b, measuring diseasefree survival and cancer relapse using medicare claims from calgb breast cancer trial participants companion to 9344, jnci. This situation might change if the ongoing phase 3 trial calgb 30610 nct00632853, comparing 45 gy twicedaily with 70 gy oncedaily in the usa, reaches different conclusions. Rtog 0539 radiation therapy oncology group rtog 0539 phase ii trial of observation for lowrisk meningiomas and of radiotherapy for intermediate and highrisk meningiomas study chairs 6910. Calgb 30610 thoracic radiotherapy for limited stage small cell. Failing to do all of the above will make the patient not. Pulmonary toxicity in stage iii nonsmall cell lung cancer. Alternatively, you can also download the pdf file directly to your computer, from where it can be opened using a pdf reader. However, patient accrual to the 45 gy and 70 gy arms is. Bhs guidelines for the treatment of burkitts lymphoma. Phase iii comparison of thoracic radiotherapy regimens in. Goals of 10403 study to estimate feasibility and dfs using a successful cog regimen in adult cooperative group setting in usa flow sheets to evaluate compliance with dosesschedule of chemotherapy to obtain insights into agespecific molecular pathogenesis and to identify prognostic markers. A pediatric regimen for older adolescents and young adults.
Radiation therapy regimens in treating patients with limited. Smallcell lung cancer sclc represents 10% to 15% of lung cancer cases and. Use the covid19 button located at the top of the ctsu members website to access the covid19 information page. Acute leukemia group b, algb is a cancer research cooperative group in the united states calgb research is focused on seven major disease areas. Interruptions of oncedaily thoracic radiotherapy do not. Patients with direct invasion of the vertebral bodies or. A phase ii study of dasatinib and dexamethasone as primary. Patients not able to be treated within 3 days of day 22 should not be registered to calgb 30610.